Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus paclitaxel vs placebo plus paclitaxel in advanced gastric cancer (Asian phase 3)
jRCT2080222339Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and esophagogastric junction cancer comparing Olaparib + paclitaxel with Placebo + paclitaxel (2 arms). Started Dec 2013; status: completed.
02
Drugs
olaparib
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2080222339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222339.